Deals
Novartis and Unnatural Products did not specify which disease targets they’re going after, only noting that the latter’s macrocyclic platform can generate potentially next-generation therapies that could apply to cardiovascular conditions.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Immuneering Corporation has announced the completion of a $17 million Series A financing.
Latest funding caps year of groundbreaking milestones for transformative vascular access company; new capital will be used to meet rapidly growing hospital and patient demand
The companies had to undergo a number of delays as regulatory agencies from across the globe looked closely at the deal to see if there was a potential the combined companies could create a monopoly in the market and stifle competition.
AELIS FARMA, a biotechnology company specialized in the treatment of brain disorders, announces the completion of a €11 million financing round from the Region Nouvelle Aquitaine, Inserm Transfert Initiative, Bpifrance and the ACI, NACO and Aelis Innovation regional funds.
CELLINK’s goal is to grow sales organically with a minimum of 35% per year and grow additionally through acquisitions.
Following a partnership with Bit Bio announced earlier this month, this morning, CRL announced the acquisition of HemaCare for approximately $380 million in cash.
UK Innovation & Science Seed Fund, Catapult Ventures’ GM&C Life Sciences Fund and Jonathan Milner are pleased to announced an investment in Pencil Biosciences, a novel gene modulation company based at Alderley Park, Cheshire.
The Beacon optofluidic technology will be used to speed the identification of lifesaving treatments for deadly viruses including Ebola, Lassa and others.
AQILION AB is selling its entire stake in the portfolio company Glactone Pharma AB to Daniel Lifveredson Invest AB.
StartX Med company Kodiak Sciences, a clinical stage company developing innovative therapeutics to treat high prevalence ophthalmic diseases, recently reached a market cap of $3.56 billion.